Literature DB >> 11329476

Oral administration of influenza vaccine in combination with the adjuvants LT-K63 and LT-R72 induces potent immune responses comparable to or stronger than traditional intramuscular immunization.

J D Barackman1, G Ott, S Pine, D T O'Hagan.   

Abstract

Mucosal immunization strategies are actively being pursued in the hopes of improving the efficacy of vaccines against the influenza virus. Our group investigated the oral immunization of mice via intragastric gavage with influenza hemagglutinin (HA) combined with mutant Escherichia coli heat-labile enterotoxins K63 (LT-K63) and R72 (LT-R72). These oral immunizations resulted in potent serum antibody and HA inhibition titers, in some cases stronger than those obtained with traditional intramuscular administration, in addition to HA-specific immunoglobulin A in the saliva and nasal secretions. This study demonstrates that it may be possible to develop effective oral influenza vaccines.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11329476      PMCID: PMC96119          DOI: 10.1128/CDLI.8.3.652-657.2001

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  37 in total

1.  Oral administration of a streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramucosal tissues.

Authors:  C Czerkinsky; M W Russell; N Lycke; M Lindblad; J Holmgren
Journal:  Infect Immun       Date:  1989-04       Impact factor: 3.441

2.  Quantification of haemagglutinin of influenza Tween-ether split vaccines by immunodiffusion.

Authors:  R Johannsen; H Moser; J Hinz; H J Friesen; H Gruschkau
Journal:  Vaccine       Date:  1985-09       Impact factor: 3.641

3.  Efficacy of influenza vaccine in nursing homes. Reduction in illness and complications during an influenza A (H3N2) epidemic.

Authors:  P A Patriarca; J A Weber; R A Parker; W N Hall; A P Kendal; D J Bregman; L B Schonberger
Journal:  JAMA       Date:  1985-02-22       Impact factor: 56.272

4.  Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ's Hospital.

Authors:  T W Hoskins; J R Davies; A J Smith; C L Miller; A Allchin
Journal:  Lancet       Date:  1979-01-06       Impact factor: 79.321

Review 5.  Serious morbidity and mortality associated with influenza epidemics.

Authors:  W P Glezen
Journal:  Epidemiol Rev       Date:  1982       Impact factor: 6.222

6.  Standardized viral hemagglutination and hemagglutination-inhibition tests. I. Standardization of erythrocyte suspensions.

Authors:  J C Hierholzer; M T Suggs
Journal:  Appl Microbiol       Date:  1969-11

7.  Recognition of monovalent sialosides by influenza virus H3 hemagglutinin.

Authors:  T J Pritchett; R Brossmer; U Rose; J C Paulson
Journal:  Virology       Date:  1987-10       Impact factor: 3.616

8.  Influenza vaccination.

Authors:  M A Riddiough; J E Sisk; J C Bell
Journal:  JAMA       Date:  1983-06-17       Impact factor: 56.272

9.  Intranasal immunization of mice with influenza vaccine in combination with the adjuvant LT-R72 induces potent mucosal and serum immunity which is stronger than that with traditional intramuscular immunization.

Authors:  J D Barackman; G Ott; D T O'Hagan
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

10.  Oral vaccination. Identification of classes of proteins that provoke an immune response upon oral feeding.

Authors:  H J de Aizpurua; G J Russell-Jones
Journal:  J Exp Med       Date:  1988-02-01       Impact factor: 14.307

View more
  6 in total

Review 1.  Recent advances in vaccine adjuvants.

Authors:  Manmohan Singh; Derek T O'Hagan
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

2.  Effects of different routes of administration on the immunogenicity of the Tat protein and a Tat-derived peptide.

Authors:  Valentina Finessi; Francesco Nicoli; Eleonora Gallerani; Fabio Sforza; Mariaconcetta Sicurella; Aurelio Cafaro; Antonella Caputo; Barbara Ensoli; Riccardo Gavioli
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Oral vaccination with inactivated influenza vaccine induces cross-protective immunity.

Authors:  Fu-Shi Quan; Richard W Compans; Sang-Moo Kang
Journal:  Vaccine       Date:  2011-11-19       Impact factor: 3.641

Review 4.  Adjuvants: Classification, Modus Operandi, and Licensing.

Authors:  Juliana de Souza Apostólico; Victória Alves Santos Lunardelli; Fernanda Caroline Coirada; Silvia Beatriz Boscardin; Daniela Santoro Rosa
Journal:  J Immunol Res       Date:  2016-05-04       Impact factor: 4.818

Review 5.  Novel approaches to vaccine delivery.

Authors:  Derek T O'Hagan; Rino Rappuoli
Journal:  Pharm Res       Date:  2004-09       Impact factor: 4.200

Review 6.  Recent advances in the discovery and delivery of vaccine adjuvants.

Authors:  Derek T O'Hagan; Nicholas M Valiante
Journal:  Nat Rev Drug Discov       Date:  2003-09       Impact factor: 84.694

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.